These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 18484799)

  • 1. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.
    Buchhalter AR; Fant RV; Henningfield JE
    Drugs; 2008; 68(8):1067-88. PubMed ID: 18484799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
    Frishman WH
    Prev Cardiol; 2007; 10(2 Suppl 1):10-22. PubMed ID: 17396063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endogenous cannabinoid system modulates nicotine reward and dependence.
    Merritt LL; Martin BR; Walters C; Lichtman AH; Damaj MI
    J Pharmacol Exp Ther; 2008 Aug; 326(2):483-92. PubMed ID: 18451315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current and future medical drugs for smoking cessation].
    Kusma B; Mache S; Deissenrieder F; Quarcoo D; Welte T; Groneberg D
    Laryngorhinootologie; 2009 Jun; 88(6):410-9; quiz 420-2. PubMed ID: 19504411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.
    Henningfield JE; Shiffman S; Ferguson SG; Gritz ER
    Pharmacol Ther; 2009 Jul; 123(1):1-16. PubMed ID: 19362108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.
    Bagdas D; Muldoon PP; Zhu AZ; Tyndale RF; Damaj MI
    Neuropharmacology; 2014 Oct; 85():67-72. PubMed ID: 24859605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options in smoking cessation.
    Crain D; Bhat A
    Hosp Pract (1995); 2010 Feb; 38(1):53-61. PubMed ID: 20469625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New possibilities in pharmacological treatment of nicotine dependence].
    Hildebrand BE; Svensson TH
    Lakartidningen; 1999 Nov; 96(47):5217-22, 5224. PubMed ID: 10608113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medications in smoking cessation].
    Mansourati J; Borel ML; Munier S; Guevel-Jointret AL
    Presse Med; 2005 Oct; 34(18):1331-6. PubMed ID: 16269998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant for treating tobacco dependence.
    Steinberg MB; Foulds J
    Vasc Health Risk Manag; 2007; 3(3):307-11. PubMed ID: 17703638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for tobacco dependence.
    Fant RV; Buchhalter AR; Buchman AC; Henningfield JE
    Handb Exp Pharmacol; 2009; (192):487-510. PubMed ID: 19184660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments.
    D'Souza MS; Markou A
    Addict Sci Clin Pract; 2011 Jul; 6(1):4-16. PubMed ID: 22003417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging pharmacotherapies for treating tobacco dependence.
    Schnoll RA; Lerman C
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):429-44. PubMed ID: 16939383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing smoking behaviour and risk through CYP2A6 inhibition.
    Sellers EM; Tyndale RF; Fernandes LC
    Drug Discov Today; 2003 Jun; 8(11):487-93. PubMed ID: 12818518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on therapeutics for tobacco dependence.
    Lancaster T; Stead L; Cahill K
    Expert Opin Pharmacother; 2008 Jan; 9(1):15-22. PubMed ID: 18076335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medication for ending tobacco dependency. Current state].
    Camarelles Guillem F
    Aten Primaria; 2005 Jun; 36(2):62-3. PubMed ID: 15989825
    [No Abstract]   [Full Text] [Related]  

  • 18. Endogenous opioid system: a promising target for future smoking cessation medications.
    Norman H; D'Souza MS
    Psychopharmacology (Berl); 2017 May; 234(9-10):1371-1394. PubMed ID: 28285326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for the treatment of tobacco dependence: 2014 update.
    Elrashidi MY; Ebbert JO
    Expert Opin Emerg Drugs; 2014 Jun; 19(2):243-60. PubMed ID: 24654737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
    Kubota T; Nakajima-Taniguchi C; Fukuda T; Funamoto M; Maeda M; Tange E; Ueki R; Kawashima K; Hara H; Fujio Y; Azuma J
    Pharmacogenomics J; 2006; 6(2):115-9. PubMed ID: 16402086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.